Stanley Center for Psychiatric Research at Broad Institute

Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer

Retrieved on: 
Monday, April 3, 2023
Mental Health, Technology, Medical Devices, Neurology, Biometrics, Other Health, Biotechnology, Health, Oncology, Artificial Intelligence, Monochorionic twins, Wyss Foundation, Hasso Plattner Institute, Berlin Institute for Advanced Study, Broad Institute, University, Wyss Center for Bio and Neuroengineering, Icahn School of Medicine at Mount Sinai, Bio, Multimedia, Research, Genomics, Mount Sinai, Translation, University of Geneva, Campus Biotech, DSM-IV codes, Digital health, MD, RTÉ Executive Board, Artificial intelligence, Psychiatry, CHF, Stanley Center for Psychiatric Research at Broad Institute, Geneva University Hospitals, Management, Pharmaceutical industry

The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.

Key Points: 
  • The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.
  • Erwin Böttinger as its new Chief Executive Officer (CEO).
  • Erwin Böttinger, Chief Executive Officer of the Wyss Center for Bio and Neuroengineering.
  • Since its founding, the Wyss Center has developed strong systems to advance vital technologies to the clinic.

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, March 21, 2023
Amgen, DNA, Novartis Institute for Tropical Diseases, Drug development, Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, CSO, Indian Institute of Science Education and Research, Thiruvananthapuram, Biotechnology, Howard Hughes Medical Institute, Research, Mount Sinai, Biomedical Research, Neuroscience, DSM-IV codes, Acquisition, Novartis, Patient, Hematology, Drug discovery, Cadent, Therapy, Stanley Center for Psychiatric Research at Broad Institute, Genome, Pharmaceutical industry, Beam, Sangamo Therapeutics

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).

Key Points: 
  • CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).
  • Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities.
  • Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
  • “We are thrilled to welcome Gopi to the Beam team during this exciting time as we advance our diverse clinical and earlier-stage pipeline of base editing programs,” said Dr. Ciaramella.

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Retrieved on: 
Thursday, July 28, 2022
Food and Drug Administration, Cognitive deficit, ERP, Ageing, CNS, Safety, Disorder, Broad Institute, MELAS, CIAS, Company, LinkedIn, Șaeș, Quantitative electroencephalography, Population, Government budget balance, CYCN, Delusion, Alzheimer's disease, Neuropsychiatry, NO, Research, Biomarker, Nitric oxide, Stanley Center for Psychiatric Research at Broad Institute, ADV, AES, Guanylate cyclase, SGC, Cognition, GLOBE, Pharmacology, EEG, CGMP, Twitter, Food, Nasdaq, Mitochondrial encephalomyopathy, Therapy, Plasma, Trial of the century, Hallucination, Psychiatry, Movement, EDT, Inflammation, Drug development, Patient, Pharmacokinetics, Physiology, Dietary supplement, Pharmaceutical industry, Medical device, Online shopping, Schizophrenia

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS) in individuals with stable schizophrenia on a stable, single, atypical antipsychotic regimen. Data from the 14-day, double-blind, randomized, placebo-controlled, multiple-ascending-dose study demonstrate that once-daily CY6463 was safe and well tolerated, with no reports of serious adverse events (SAEs), severe adverse events (AEs), or treatment discontinuation due to AEs. Study data demonstrate a strong effect on cognitive performance after two weeks of 15mg once-daily dosing. A broad positive movement on inflammatory biomarkers was also observed. These signals on exploratory endpoints provide further evidence of the pro-cognitive and anti-inflammatory effects of CY6463 observed in preclinical studies and prior clinical trials.

Key Points: 
  • I am encouraged by the promising cognition signals observed after only two weeks of CY6463 dosing in patients with stable schizophrenia.
  • These data demonstrate the therapeutic potential of amplifying sGC signaling in the CNS, including positive effects on cognition and inflammation, and support further development of CY6463 in diseases characterized by cognitive impairment.
  • The clinical study enrolled 48 participants with stable schizophrenia with no more than moderate positive symptoms and on a stable, single, atypical antipsychotic regimen.
  • Cognitive impairment is a core, debilitating, and untreated symptom of schizophrenia, with nearly all patients suffering from some cognitive deficits.

DBSA BOARD CHAIR KENT DAUTEN SUPPORTS EFFORT TO DESTIGMATIZE YOUTH MENTAL HEALTH WITH UNDERWRITING OF KEN BURNS DOCUMENTARY: “HIDING IN PLAIN SIGHT”

Retrieved on: 
Monday, June 27, 2022
Death, Life, PBS, Hallucination, History, Broad Institute, Awareness, Central Time, Suicide, Hospital, Clinical professor, Mayo Clinic, Organization, Depression, WTTW, Mental disorder, Family, Stanley Center for Psychiatric Research at Broad Institute, Massachusetts General Hospital, Mental health, Center, Program, Education, Medicine

The more we learn about the struggles young people experience in managing their mental health, the more important education and awareness become in the battle to fight stigma associated with youth mental health.

Key Points: 
  • The more we learn about the struggles young people experience in managing their mental health, the more important education and awareness become in the battle to fight stigma associated with youth mental health.
  • The Dauten Family Foundation, a private, Chicago-based foundation, has a deeply rooted history of philanthropy to support the health sciences.
  • This week, the foundation demonstrates another example of its commitment to mental health philanthropy as an underwriter of a new PBS documentary series, Ken Burns Presents Hiding in Plain Sight: Youth Mental Illness, premiering June 27 and 28 at 9 p.m.
  • The Dauten Family Foundation is proud to support the important Ken Burns documentary Hiding in Plain Sight and hopes it encourages more discussions around how we can eliminate stigma in youth mental health.

Top Birth Defects Researchers to Convene in Vancouver

Retrieved on: 
Wednesday, May 4, 2022
Texas A&M Health Science Center, New York University Grossman School of Medicine, Ottawa Hospital Research Institute, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, University Health Network, Spectrum, Hyperglycemia, Birth, Stanley Center for Psychiatric Research at Broad Institute, Mentorship, Research, Baylor College of Medicine, Doctor of Philosophy, Hyatt Regency London – The Churchill, Toronto, Infant, Industry, Genomics, Machine learning, Hyatt, Nathan Kline Institute for Psychiatric Research, Center, University School, Master of Science, Reproduction, Annual general meeting, Ventricular septal defect, Risk, Social media, Pharmaceutical industry, Dentistry, Medicine, Society, Medicine

VANCOUVER, British Columbia,  May 4, 2022 /PRNewswire-PRWeb/ --From the use of a global birth defects app in low resource settings to examining maternal hyperglycemia and the risk for congenital heart disease, some of the world's top scientific minds will be recognized for their cutting-edge birth defects-related research. Award recipients and special lecturers will be honored during the Society for Birth Defects Research and Prevention's 62nd Annual Meeting being held in-person June 25-29, 2022, at the Hyatt Regency Vancouver in Vancouver, British Columbia, Canada.

Key Points: 
  • VANCOUVER, British Columbia, May 4, 2022 /PRNewswire-PRWeb/ --From the use of a global birth defects app in low resource settings to examining maternal hyperglycemia and the risk for congenital heart disease, some of the world's top scientific minds will be recognized for their cutting-edge birth defects-related research.
  • Award recipients and special lecturers will be honored during the Society for Birth Defects Research and Prevention's 62nd Annual Meeting being held in-person June 25-29, 2022, at the Hyatt Regency Vancouver in Vancouver, British Columbia, Canada.
  • The conference will include important and emerging topics such as infant mortalities due to birth defects in underserved communities, genomics of structural birth defects, the use of machine learning to classify congenital malformations, and much more.
  • The Society for Birth Defects Research and Prevention (BDRP) is an international and multidisciplinary group of scientists who study birth defects, reproduction, and disorders of developmental origin.

Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases

Retrieved on: 
Thursday, October 7, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, EEG, Company, Twitter, Patient, Investment, Greater Boston, Broad Institute, Therapy, Genomics, SAB, Stanley Center for Psychiatric Research at Broad Institute, Central nervous system disease, Johns Hopkins School of Medicine, Onyx Pharmaceuticals, Lists of diseases, Drug development, Time, Genetics, Probability, Cancer, Industry, Neurodegeneration, Psychiatry, Apeiron, TAB, Precision, Neurological disorder, Data science, Amgen, Polaris Partners, Disease, Neuroscience, Medical imaging, Pharmaceutical industry, Management

Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch today.

Key Points: 
  • Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch today.
  • Neumora is built at scale to pioneer potential best-in-class precision medicines for brain diseases, and we believe that integrating data sciences is the key.
  • We built Neumora to pioneer the future of precision medicines for brain diseases.
  • Neumora Therapeutics, Inc. is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Cohen Veterans Bioscience Issues National PTSD Awareness Day Progress Report

Retrieved on: 
Thursday, June 27, 2019
Psychiatry, Articles, Aftermath of war, Military, Abnormal psychology, Military personnel, Posttraumatic stress disorder, Psychiatric diagnosis, RTT, Stanley Center for Psychiatric Research at Broad Institute

Cohen Veterans Bioscience, in collaboration with the Stanley Center for Psychiatric Research, provided funding to support the largest genome-wide association study of PTSD to date.

Key Points: 
  • Cohen Veterans Bioscience, in collaboration with the Stanley Center for Psychiatric Research, provided funding to support the largest genome-wide association study of PTSD to date.
  • This study involved more than 60 multi-ethnic datasets including more than 30,000 PTSD cases and 170,000 controls contributed by the Psychiatric Genomics Consortium (PGC) PTSD Working Group.
  • This global, landmark study has identified six genome-wide significant loci involved in PTSD risk, and implicates novel biological pathways in PTSD.
  • We are delivering upon the approach and leveraging enabling platforms to deliver these results across many fronts," said Magali Haas, President and CEO, Cohen Veterans Bioscience.